On May 22, Insilico Medicine (03696.HK) rose 5.19% in regular trading, trading at 48.14 HKD/share, with trading volume of approximately 72.90 million HKD.

On the news front, Insilico Medicine and Saudi Aramco jointly developed and released a systematic AI screening and verification system called Sanity Pipeline, targeting the design of Nobel Prize-winning Metal-Organic Framework (MOF) materials. The system aims to enhance both the speed and accuracy of MOF research and development, with findings recently published on ChemRxiv.

The Sanity Pipeline integrates efficient pre-screening with in-depth verification. Core models co-developed by both parties include LibCIF, a tool for efficient MOF decomposition and structural analysis, and OxiChecker, a detector for identifying oxidation state anomalies. The two companies previously signed a strategic cooperation agreement during the LEAP technology conference, empowering AI-driven sustainable development and anti-aging research.

Insilico Medicine is a globally recognized AI-driven drug discovery and development company. Its proprietary generative AI platform Pharma.AI has produced over 20 clinical or IND-stage assets, with three licensed to international pharmaceutical companies at a total contract value of up to $2.1 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)